Marilena Vrana: Securing Sustainable Plasma Supply for Europe’s Growing Patient Needs
Marilena Vrana, Vice President at the Plasma Protein Therapeutics Association (PPTA) Europe, shared a post on LinkedIn:
“I was glad to join with my PPTA colleagues Anita Brikman, James Knowles and Halide Tuna, the 2026 IPFA/EBA Symposium on Plasma Collection and Supply in Leuven this week.
The discussions focused on both progress and ongoing challenges in meeting plasma need for the growing patient need for plasma-derived medicines, including immunoglobulins and other life-saving and life-enabling therapies.
During the exchanges with peers, I emphasized that ‘self-sufficiency’ should be addressed through a multi-stakeholder dialogue that includes patients and physicians. It must be viewed through the lens of European strategic autonomy – not only national capacity and self-sufficiency – and grounded in actual patient need.
While patient need is still not comprehensively recorded across all Member States, data show that it continues to grow steadily in Europe and globally, driven by improved diagnostic technologies, new indications, and evolving disease detection strategies.
Ensuring patients’ long-term peace of mind requires that we align policy ambition with real-world demand.
There is a clear opportunity for more aligned strategies across stakeholders – from streamlining contract fractionation arrangements to strengthening resilient supply chains that better serve patients in Europe and beyond.
Stronger public-private partnerships, supported by data and best practices, will be critical to closing availability gaps and advancing our collective responsibility to secure long-term sustainability of supply.
I look forward to continuing the dialogue at PPC2026 in Milan – an important checkpoint for our community – where the private sector’s role in strengthening Europe’s Resilience, Reach and Responsibility in plasma and plasma derived medicines will be further discussed.
Together, we can continue moving faster and further in delivering for all patients.”

Find more posts featuring Marilena Vrana on Hemostasis Today.
-
Nov 18, 2026, 01:45Shikha Jha: My Takeaways from the 4th GANSID International Congress
-
Nov 18, 2026, 01:34Zeeshan Ahmed Khattak: Treatment of Fever and Neutropenia in Hematology/Oncology and Hematopoietic Cell Transplant Patients
-
Nov 17, 2026, 23:45Cajetan Reichardt: LAAO vs. OAC in AF – Balancing Nonprocedural Bleeding and Ischemic Stroke Risk
-
Nov 17, 2026, 23:42Brian Tegtmeyer: Expanding Pre-Hospital Administration of Low-Titer O Positive Whole Blood
-
Nov 17, 2026, 23:41Mansi Kala: Advancing Hematology – From Evidence to Clinical Excellence
-
Nov 17, 2026, 23:40Nathan Connell: Registered for the WFH Comprehensive Care Summit 2027 in Prague
-
Nov 17, 2026, 23:38Yaariv Khaykin: Does Reducing AF Burden After Ablation Change the Need for Anticoagulation?
-
Nov 17, 2026, 23:38Amos Gitonga Mbaabu: Strengthening Care and Advocacy for Haemophilia and SCD across Southern Africa
-
Nov 17, 2026, 23:35Muhammad Sameed Altaf: A Decade of Working Together for Thalassemia Awareness and Patient Support